Immunitor Inc.

oral immunotherapy company with numerous published clinical trials in multiple diseases, with most recent success against terminal liver cancer.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Vancouver, BC, Canada
  • Currency CAD
  • Founded September 2010
  • Employees 20
  • Incorporation Type Other
  • Website immunitor.com

Company Summary

Immunitor is a global oral vaccine corporation. For two decades, many successful clinical trials are published in peer-reviewed journals. The most recent Hepko-V5 (hepcortespenlisimut-L, for liver cancer) and Tubivac (M. vaccae, for tuberculosis) Phase III clinical trials published January 2020 are available in two press releases with details:
https://www.prweb.com/releases/prweb16874458.htm
https://www.prweb.com/releases/prweb16874150.htm

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free